白细胞介素-6在非小细胞肺癌中的临床意义  

The clinical significance of serum interleukin-6 levers in non-small cell lung cancer patients

作　　者：张林杰[1] 汪伟民[2] 庞玉瑛[2] 马维通[2] 

机构地区：[1]安徽医科大学免疫学教研室,合肥230032 [2]安徽医科大学附属医院呼吸内科,合肥230022

出　　处：《安徽医科大学学报》2002年第3期198-199,240,共3页Acta Universitatis Medicinalis Anhui

摘　　要：目的　了解白细胞介素 6 (IL 6 )在非小细胞肺癌(NSCLC)的诊断及分期、分型等方面的意义。方法　用酶联免疫吸附法 (ELISA)测定 6 1例NSCLC患者血清IL 6水平 ,并与非肿瘤组及正常组相比。结果　肺癌组血清IL 6水平(11 80 3± 8 35 7) μg/L明显高于正常组 (7 2 6 3± 4 36 5 )μg/L(P <0 0 1) ,而低于非肿瘤组 (17 4 14± 17 12 8) μg/L ;随着肺癌分期的增高 ,IL 6的水平有逐渐增高的趋势 ,Ⅳ期又有所降低 ;肺癌组内各型间IL 6水平差异无显著性。结论　血清IL 6水平与NSCLC的分期有关 ;结合临床资料 。Objective To understand the clinical significance of interleukin 6 (IL 6) levels in non small cell lung cancer (NSCLC) Methods To measure the serum levels of IL 6 in patients with NSCLC, and benign lung disease and the healthy group by enzyme linked immunosorbent assay (ELISA) Results The mean serum IL 6 levels in patients with NSCLC was higher than in the healthy ( P <0 01) and lower than in benign lung disease group ( P <0 05) The serum IL 6 levels in each stage of NSCLC was different respectively stage Ⅲ a, stage Ⅲ b and stage Ⅳ had significantly higher serum IL 6 levels than stage Ⅰ a～Ⅱ b ( P <0 05), but serum IL 6 levels in stage Ⅲ a, stage Ⅲ b and stage Ⅳ were not significantly different ( P <0 05) From stage Ⅰ a～Ⅱ b to stage Ⅲ b, the serum IL 6 levels waere gradually increased, but the serum IL 6 level in Ⅳ stage was decreased slightly Serum IL 6 levels in each type of NSCLC were not signifi cantly different ( P >0 05) Conclusion The increased IL 6 level canbe considered as supplementary diagnostic factor of NSCLC; Serum IL 6 levels may be treated as the reference of judging each stage of NSCLC and predicting prognosis.

关 键 词：白细胞介素-6 非小细胞肺癌 临床意义 诊断 

分 类 号：R734.2[医药卫生—肿瘤]